AD/PD 2023 | Symptomatic versus disease modifying treatments

Suzanne Hendrix, PhD, Pentara Corporation, Salt Lake City, UT, explains how a patient’s condition while on disease modifying therapy is a more accurate representation of their true disease state. Symptomatic therapies temporarily mask the symptoms of disease which may return when treatment is terminated, as the underlying drivers are not being impacted. Whereas, the benefits achieved whilst receiving disease modifying therapies are not nullified upon discontinuation, whether this is damage reversal or slowing of the disease process. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.